International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP)

IJRPP |Vol.14 | Issue 4 | Oct - Dec -2025

www.ijrpp.com

ISSN: 2278-2648

DOI : https://doi.org/10.61096/ijrpp.v14.iss4.2025.868-881

Research

NEW IMMUNOMODULATORY APPROACHES TO ALLERGIC INFLAMMATION: BIOLOGICS, SMALL MOLECULES, AND INNOVATIVE VACCINES

Rohit kumar panda[1], Thalasani Soumya[2*], Yeligeti Navya[3], Dr. Padige Srivarsha[4]

[1,2,3]*Pharm-D 4th year, Malla Reddy College of Pharmacy, Dhulapally, Secunderabad , Telangana-500100.*

[4]*Associate Professor, Clinical Pharmacy Practice Department, Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana-500100.*

[*]Author for Correspondence: Thalasani Soumya
Email: thalasanisoumyareddy@gmail.com

Published on: 21.12.25

Published by:
Futuristic Publications

Abstract

A true public health emergency has resulted from the exponential increase in the prevalence of allergic diseases since the middle of the 20th century, which has also greatly advanced research into the underlying mechanisms and possible cures. The biological revolution has improved the treatment of allergic diseases by providing a variety of new **immunomodulatory therapeutic** and research tools that target the factors that contribute to allergic inflammation at separate pathophysiological processes. Notable examples include small-molecule modifiers of **signal transduction**, which are primarily mediated by Janus kinases and Bruton's tyrosine kinases, as well as therapeutic **monoclonal antibodies** against cytokines, alarmins, and their receptors. Nevertheless, the primary treatment options have not yet transitioned from symptomatic to disease-modifying measures.In light of our current knowledge of allergy pathophysiology, we provide an overview of the medications currently on the market, suggest possible therapeutic targets, and wrap up by listing a few candidate immunopharmacological molecules that are being researched for possible **future application in allergic diseases**.

Keywords: Allergy, biologics, eosinophils, immunopharmacology, mast cells, small-molecule drugs.

INTRODUCTION:

Chronic Noncommunicable diseases like allergies and hypersensitivity are linked to lifestyle choices and environmental exposure[1]. According to data on the global burden of disease for 2019, there are more than 260 million cases of asthma and 170 million cases of atopic dermatitis (AD)[2]. Chapter 3 of the World Health Organization's International Classification of Diseases 11 contains ground breaking sections on immune system hypersensitivity and allergy disorders[3]. Intolerance and sensitivity include a wide range of conditions, such as urticaria (hives), asthma, chemical and food allergies, allergic rhinitis (AR; hay fever), (rhino)conjunctivitis, chronic rhinosinusitis with nasal polyps (CRSwNP), AD (eczema), and anaphylaxis, a medical emergency that can be fatal.These conditions are characterized by abnormal type 2 (T2) immune responses, either in duration or intensity, to a stimulus that non affected people would typically tolerate. Damage to the structure and function of the afflicted organs results from untreated chronic allergic inflammation (ALLINF)[4].

A wide variety of cells are involved in the development of ALLINF, which is triggered by non-infectious, frequently harmless environmental insults. Downstream activation signals are produced when allergen crosslinking of nearby immunoglobulin (Ig) E molecules attached to their high-affinity receptors (FcεRI) on sensitized mast cells (MCs) and basophils[5]. Three separate, consecutive phases are usually seen following MC activation. The release of primarily preformed mediators and freshly synthesized arachidonic acid metabolites characterizes the early phase, which lasts between seconds and minutes. Eosinophils (Eos), macrophages (Mφ), lymphocytes, and other immune cells migrate and infiltrate the site of MC activation during the late phase, which occurs a few hours later[6]. With repeated or extended exposure to the allergen, a third (chronic) phase is maintained[4]. Remarkably, ALLINF is comparable to enteric helminth-induced inflammation, including T2 and IgE responses, and ectoparasites: T2 responses are constructed by the epithelial barrier, group 2 innate lymphoid cells (ILC2s), and their adaptive T helper (Th) 2 counterparts. Eos are key ALLINF propagators, whereas MCs and IgE are acknowledged initiators and orchestrators of the disease[7][8]. Over the past few decades, extensive research has improved this condensed interpretation of ALLINF. (The reader is referred to the sidebar titled Endotypes and Phenotypes of Allergic Inflammatory Diseases.) The new mechanistic insights (endotypes) also offer a better understanding of the complexity of clinical manifestations (phenotypes)[9][10].

ETIOLOGY:

A high prevalence in the population of the West and a rising prevalence in developing nations indicate that elements such as western lifestyle which is spreading around the globe, could be important. Changes in the level of air pollution, indoor exposure to allergens and general living standards may be additional environmental factors associated with the risk of allergy. The hygiene hypothesis, a concept related to lifestyle changes,proposes that early and repeated childhood infections reduce the tendency to develop AD[9][10]. This is supported by the fact that children in western countries who are protected from infections due to their cleaner and germ-free surroundings are at an increased risk of developing allergy. On the other hand, infants and children in developing countries are frequently exposed to infections.Early infection exposure is caused by issues with overcrowding, malnutrition, clean drinking water, and sanitation. In addition to bacterial, viral, and parasitic infections, intestinal colonization with Gram-negative bacteria typically happens early in life. In Europe, children with allergies and those without have different intestinal flora[11].

The risk of developing AD may also be increased by antibiotic use during the first two years of life[12].The normal development of the immune response (Th1 and Th2) is typically promoted by a balanced exposure to microbes, parasites, allergens, and other environmental substances[13]. However, genetically predisposed people are more likely to have an exaggerated Th2-cell type response to a range of allergens as their exposure to them increases & function and reduces Th1 and Th2 reactions brought on by either the innate or adaptive immune systems being activated[14][15].



GENETIC AND EPIGENETICS:

One of the major etiological factors for allergies was thought to be genetic. Hundreds of genes linked to asthma have been identified through the extensive use of genome-wide association studies.or other ADs have recently been discovered. These genes have assisted us in comprehending a number of pathways essential to the etiology of allergies, even though a conclusive etiological connection has not yet been established. The genes can be categorized as either regulating immune function or affecting structural tissues such as connective tissue or epithelium, depending on their relationship to the innate or adaptive immune response[16].

Another significant way that environmental factors may interact with genes implicated in the development of AD is through epigenetic regulation[17][18]. It has recently been demonstrated that DNA.The development of allergic diseases is largely dependent on the genes IL-4 and IL-13. They play a role in the development of Th2 cells and the synthesis of IgE antibodies, two essential elements of allergic reactions.

ADRB2: This gene is linked to the relaxation of respiratory smooth muscle and encodes the beta-2 adrenergic receptor. The way the airways react to allergens can be impacted by variations in this gene.

HLA-DRB1: This gene contributes to the immune system's reaction to allergens and is involved in antigen presentation.

CD14: This gene can be connected to allergic reactions and plays a role in the interplay between the immune system and environmental factors.

The gene FLG (Filaggrin) is linked to the skin barrier. FLG mutations can result in a weakened skin barrier, making people more vulnerable to allergic reactions[19][20].The gene FLG (Filaggrin) is linked to the skin barrier. A weakened skin barrier brought on by mutations in FLG can make a person more vulnerable to allergic sensitization, eczema, and food allergies.

ORMDL3: This gene is associated with a higher chance of developing asthma at a young age.

GSDML: This gene is linked to early-onset asthma, just like ORMDL3.

ADAM33: This gene can be linked to hyperresponsive airways in allergic conditions and is involved in tissue remodeling.

STAT6: This gene contributes to allergic reactions and Th2 cell differentiation.

CDHR3: Variants in this gene, which codes for a protein involved in the function of epithelial cells, are linked to exacerbations of severe asthma[21].

CELL AND CHEMICAL MESSANGERS IN ALLERGY:

A series of interactions between different inflammatory and structural cells via their chemical messengers results in an allergic inflammatory response, which collectively causes allergy symptoms[22].

IGE AND ITS RECEPTORS :

The two main receptors for IgE, FcRI (high-affinity receptor for IgE) and FcRII (low-affinity receptor), are two components of the protein network that includes IgE, which is essential for allergic inflammation[23].

A preexisting complex of an IgE antibody attached to its high-affinity receptor FcRI on the membrane of mast cells and basophils captures the allergen during an allergic reaction. This causes the IgE–FcRI complex to crosslink, which in turn causes these cells to become activated and release chemicals that cause allergy symptoms. IgE-mediated mast cell activation depends on the quick IgE–FcRI interaction made possible by FcRI's high affinity for IgE.There are two splice variants of the low-affinity receptor CD23: CD23a and CD23b. Antigen-activated B cells express CD23a prior to their differentiation into plasma cells that secrete antibodies [24].

On the other hand, IL-4 causes a range of inflammatory cells, B cells, and epithelial cells to express CD23b. The primary function of CD23 is to regulate the synthesis and maintenance of IgE. IgE has several allergic functions, such as causing immediate hypersensitivity by forming an IgE–FcRI complex on mast cells, which causes them to degranulate and cause allergies in the skin (atopic dermatitis or eczema), nose (AR), eyes (conjunctivitis), lungs (asthma), or gut (food allergy); presenting antigen by bindingto APCs; assisting eosinophils and monocytes in lysis and phagocytosis of the resulting cell fragments, then binding to DCs and mastcells throughFcRI[25][26].



MASTER CELLS:

Three categories of physiologically active products are released by the mast cells upon activation: those found in cytoplasmic granules; lipid-derived mediators; as well as recently produced growth factors, chemokines (CCs), and cytokines. The mast cell granules' membrane unites with the plasma membrane during degranulation,

exposing the contents to the outside world. Histamine, heparin, chondroitin sulfate, tryptase, chymase, carboxypeptidase, specific cytokines, and growth factors are among the significant mediators released.

The mediators released cause vasodilatation, bronchoconstriction, and plasma exudation, which results in symptoms of either AR (nasal blockage and mucus) or asthma (dyspnea and wheezing). Cytokines like IL-9 and stem cell factor keep mast cells in the tissue and on the mucosal surfaces[27].

DENDRITIC CELLS:

Human DCs are classified as CD11c+ myeloid DCs and CD11c− (CD123+ CD303+ CD304+) plasmacytoid DCs.

There are additional subsets of myeloid DCs based on differential CD1c, CD141, and CD16 expression[28]. The epithelial cells that line the airway lumen or surface are where DCs extend their processes[29]. Without compromising the epithelial barrier, they detect allergenic molecules by forming tight junctions with nearby epithelial cells. Toll-like receptors (TLRs) on DCs recognize pathogen-associated molecular patterns of allergens. They then start maturing and enhance their homing by upregulating CC receptors, which then point them in the direction of the lymph nodes' T-cell zone. While plasmacytoid DCs are in charge of tolerance development and antiviral defense, myeloid-type DCs primarily function as APCs.

The DCs generate CCs, such as CCL2, CCL3, CCL4, CCL17, CCL22, and CXCL8, in response to the stimulus, which results in the recruitment of at the location of allergen exposure, of different inflammatory cells[30]



TH2 CELLS:

By releasing interleukins like IL-4, IL-5, IL-9, and IL-13, Th2 cells control allergic inflammation[31]. The allergic peptides are processed and presented to naive T cells by the APCs. When CCs like CCL17 and CCL22 are combined with IL-4 released by mast cells, eosinophils, or T cells, naive T cells differentiate into Th2 cells, which encourage the growth of B cells and the production of IgE.An invariant variable region T-cell receptor a-chain 14–joining region 18 (V(a)14–J(a)18) is present in invariant natural killer T cells[32][33].One special characteristic of these cells is their ability to react to glycolipid antigens.instead of the peptide antigens displayed by the class I MHC-like protein CD1d, which is nonpolymorphic and expressed on APCs. They are thought to be in charge of the emergence of tissue damage, cell lysis, and allergen-induced airway hyperreactivity.

INVARIANT NATURAL KILLER T CELLS:

An invariant variable region T-cell receptor a-chain 14–joining region 18 (V(a)14–J(a)18) is present in invariant natural killer T cells[33].

One special characteristic of these cells is their ability to react to glycolipid antigens.instead of the peptide antigens displayed by the class I MHC-like protein CD1d, which is nonpolymorphic and expressed on APCs. They are thought to be in charge of the emergence of tissue damage, cell lysis, and allergen-induced airway hyperreactivity[34].

TH17 CELLS:

Unlike Th1 or Th2 cells, Th17 cells are a unique T-cell lineage with a different developmental trajectory. IFN-g and IL-4 inhibit their production. Th17 cells contribute to neutrophils and monocyte recruitment, which results in allergen phagocytosis, elimination, and the development of chronic allergic inflammation[31]. Additionally, it has been demonstrated that they are in charge of bronchial asthma's resistance to corticosteroids[35]. These cells generate IL-22, IL-17A, and IL-17F. IL-17A and IL-17F cause fibroblasts, neutrophils, eosinophils, epithelial and endothelial cells, and GM-CSF to secrete IL-6, CXCL10, and CXCL8[36].

TH9 CELLS:

Th9 cells are subsets of Th2 cells that produce IL-9 and are dependent on TGF-b and IL-4[37]. These cells are distinct because they lack the transcription factors T-bet, GATA3, RORgt, and Foxp3.From inducible Tregs, Th1, or Th17. During an allergen challenge, IL-9 expression is noticeably elevated[38]. It has also been observed that mast cells, basophils, and eosinophils produce IL-9.Especially in ADs like asthma. Mucus production, subepithelial fibrosis, and the release of inflammatory mediators are IL-9's main functions[39].

NATURAL KILLER CELLS:

It has been proposed that the innate and adaptive Th2 responses in AD are connected by a newly identified cell called the nuocyte, an innate, Th2 immune effector leukocyte[40].They multiply in response to IL-25, IL-33, notch signaling, and RORgt activation, which are all derived from epithelial cells[41]. They are thought to be an early source of IL-13, particularly in cases of helminthic infestation. It is necessary to further define their role in ADs.

T SUPPERSSOR CELLS:

Tregs are in charge of reducing tolerance and the allergic reaction. They can be found naturally (thymus-derived) or artificially, and they express the transcription factors FoxpP3, CD4, and CD25.or iTreg or Tr1 inducible forms[42]. IL-10 and TGF-b, which are secreted by naturally occurring Tregs, inhibit DCs involved in effector T cell programming. In addition to preventing effector T-cell migration into the target tissue, they also inhibit Th1, Th2, and Th17 cells, allergen-specific IgE, and the induction of IgG4, mast cells, basophils, and eosinophils[43]. Protection against allergies in prenatal exposures has also been connected to an increase in the number of Tregs in circulation.



B LYMPHOCYTES:

B cells produce IgE in the draining lymph nodes, in the mucosal lymphoid tissue, or at the site of inflammation when IL-4, IL-13, and IL-9 are present. They could also serve as A APCs may also have a regulatory function by secreting IL-10[44].

EOSINOPHILS :

Th2 cells control eosinophils by releasing IL-5, and they are frequently found at the site of allergic inflammation. Additional factors that can prime them include IL-3, IL-5, GM-CSF, platelet-activating factor (PAF), and CC (CCL2, CCL3, CCL5, CCL7, CCL8, CCL11, and CCL13)[45]. By releasing cysteinyl leukotrienes (Cyst-LTs), which are also generated by mast cells and basophils, eosinophils aid in the pathophysiology of allergic symptoms. By interacting with the target cells' (i.e., epithelial cells') Cyst-LT receptors, these lipid mediators encourage allergic inflammation through eosinophil adhesion, migration, and survival as well as the production of specific proinflammatory cytokines[46].

BASOPHILS :

Following re-exposure to allergens, basophils degranulate similarly to mast cells. Histamine-releasing mediators, including CCL11, CCL24, CCL26, CCL7, CCL13, CCL5, IL-3, IL-5, and GM-CSF factor increases the effects of FcRI, which causes the release of basophil mediators[47]. Furthermore, CCL11 and CCL24 serve as basophil chemoattractants. Histamine, eicosanoids, leukotrienes (LTs), IL-4, and IL-13 are among the numerous mediators secreted by basophils[48].

In the later stages of allergic inflammation, the released cytokines play a significant role.

NEUTROPHILS :

LTB4, CXCL1, CXCL8, and IL-17 all influence the elevation of neutrophil levels at the site of allergic inflammation. Lipids are among the many products they are able to produce.

Thromboxane A2, LTA4, LTB4, PAF, cytokines (IL-1, IL-6, TNF-a, TGF-b, CXCL8), proteases (elastase, collagenase, matrix metalloproteinase 9), microbicidal products (lactoferrin, myeloperoxidase, lysozyme), and reactive oxygen species (superoxide, hydrogen peroxide, OH- and nitric oxide (NO). Airway narrowing and increased mucus secretion are caused by neutrophil products[49].

NOVEL IMMUNOPHAMACOLOGICAL DRUGS AND ALLERGY THEAPY:

SMALL MOLECULES TARGETING G PROTEIN COUPLED RECEPTORS:

JAK inhibitors' mode of action. Receptor subunit dimerization frequently happens after a cytokine binds, as is the case with granulocyte-macrophage colony stimulating factor, IL-4, IL-5, and IL-3, among others. After attaching themselves to the dimerized receptor subunits, JAKs transphosphorylate and phosphorylate the receptor's intracellular tyrosine residues (red arrows). The JAKs also phosphorylate STAT proteins, which subsequently dock at phosphorylated tyrosine residues. Following their dimerization and translocation to the nucleus (black arrows), the phosphorylated STATs act as transcription factors that control a number of cellular functions, such as immune response, growth, and differentiation. Small-molecule JAK inhibitors have become available as treatment options for preventing JAKs from propagating signal transduction, which results in immunosuppressive effects. The four members of the JAK family are specifically TYK2, JAK1, JAK2, and JAK3. Different JAK inhibitors have different levels of affiniy and selectivity for these kinases[50].



TLR AGONIST :

Activation of Innate Immunity: Damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) are recognized by TLRs, which are pattern recognition receptors. The innate immune system is activated when a skin cell's TLR comes into contact with a ligand (PAMP or DAMP) and starts a signaling cascade[51].

Production of Cytokines: TNF-α, IL-6, and IL-1β are among the cytokines that are produced as a result of this activation and are essential for tissue repair and inflammation. The overproduction of these cytokines can lead to allergic inflammation and skin disorders like atopic dermatitis and allergic contact dermatitis, even though they are necessary for preventing infections and healing damage.

EX: Imiquimod, a TLR7/8 agonist, is used to treat skin cancer and viral infections by causing an inflammatory response in the skin[52]. The potential of TLR9 agonists in cancer treatment is also being studied. TLR agonists can make allergic reactions worse by encouraging the release of cytokines and inflammation.

TLR Agonists in the Development of Vaccines:

In order to improve the immune response to the vaccine antigen, TLR agonists are also utilized as adjuvants in vaccines. This could imply that TLR agonists could be used to strengthen the immune system's reaction to allergens in the context of allergies, which could result in tolerance or desensitization[53].

TLR ANTAGONISTS :

Allergic Reactions and TLR Antagonists:It functions by preventing TLRs from attaching to their ligands, which stops the inflammatory signaling cascade from starting.

Reducing Inflammation: Antagonists can help lessen the production of inflammatory cytokines and chemokines by blocking TLR activation, which may help to alleviate allergic symptoms.

Possible Therapeutic Uses: TLR antagonists are being investigated as possible treatments for sepsis, inflammatory disorders, and autoimmune diseases. TLR antagonists may be used to lessen symptoms of skin allergies by reducing the inflammatory response.

Examples: A number of TLR antagonists are being developed clinically for inflammatory diseases, including NI-0101 (a TLR4 inhibitor) and OPN-305 (a TLR2 inhibitor)[54].

H4 RECEPTOR ANTAGONISTS :

MCs, monocytes, eosinophils, dendritic cells (DCs), T cells, and natural killer cells are among the immune system cells that primarily express the histamine H4 receptor, a pertussis-toxin-sensitive GPCR; in peripheral tissues like the spleen, thymus, colon, blood leukocytes, and bone marrow, its expression that is changed or triggered by inflammatory stimuli.When compared to the H1 receptor, the H4 receptor seems to have a greater affinity for histamine, and its activation results in leukocyte increases in intracellular Ca2+ concentration and chemotaxis to inflammatory sites through Gai/o proteins. Apart from histamine According to reports, the liver-expressed chemokine LEC/CCL16 is a non-histamine endogenous H4 receptor agonist that contributes to eosinophil trafficking and exhibits additive effects with histamine. The H4 receptor's expression across various human.The chemotactic characteristics of immune cells indicate its function in immunomodulation. The similar tissue distribution indicates that this receptor plays similar physiological roles in all species, despite interspecies variations in amino acid sequence, expression levels, ligand binding, and receptor activation[55][56].

EMERGING PLANT DERIVED DRUGS:

The phytochemicals' mechanism or mode of action can be divided into two categories according to the methods used to assess their effectiveness: in vitro and in vivo.assays. The in vitro assay examines cellular and humoral immune molecular mechanisms, whereas the in vivo assay focuses on defending host cells against infections. As a result, the review's tool does not go into detail about pharmacodynamics and pharmacokinetics but rather relies on in vitro and in vivo assays. Stated differently, there isn't a thorough discussion of immunomodulatory drug activity[57].

PHENOLIC AND FLAVONOID COMPOUND:

Resveratrol, stilbene, and phytoalexin are the sources of this compound. The primary sources are peanuts, red wine, and grapevines. The Resveratrol's immunostimulant properties result from its suppression of iNOS production in macrophages activated by lipopolysaccharide (LPS) [38]. L-arginine is converted to L-citrulline and nitric oxide (NO) by the enzyme nitric oxide synthases (NOS). As a radical, NO targets parasites, bacterial infections, and tumor growth in addition to acting as a cellular signaling molecule in response to cytokines[38]. Reducing NO production is crucial, though, particularly in certain situations when treating cancer. A protein known as chemically inducible NOS (iNOS).



ALKALOIDS :

Cocaine is a known alkaloid that comes from the two coca plant species, Erythroxylum coca and Erythroxylum novogranatense. The immune system is impacted by releasing IL-1a, IL-6, and TNF-a, which activates macrophage and splenocyte function; splenocytes also release IFN-γ, IL-2, IL-4, IL-5, and IL-10[38]. Furthermore, alkaloids with immunomodulatory activity are depicted .

VACCINES BASED ON SELECTED UNMODIFIED RECOMBINANT ALLERGENS :

Two different published clinical trials have already provided evidence of this strategy's efficacy. Patients with grass pollen allergies received treatment in the first immunotherapy trial using an mixture of the five main pollen allergens for Timothy grass (rPhl p 1, 2, 5a, 5b, and 6). Modification of the specific immune response with increased IgG and decreased IgE antibodies was linked to a clinical benefit. Another study compared the use of purified natural Bet v 1 standard extract therapy or a placebo to the treatment of birch pollen-allergic patients with the recombinant major birch pollen allergen, rBet v 1[58][59].

A single allergen was shown to be just as effective as the purified natural allergen, which contained multiple isoforms, in this multicenter study involving 134 patients and complete extract of birch pollen. Additionally, sublingual use of Recombinant Bet v 1 has been studied[60].

Since unaltered recombinant allergens possess immunological characteristics .They run the same risk of causing negative allergic reactions due to IgE or T cell reactivity as their natural counterparts. Numerous approaches have been developed to enhance SIT vaccines in order to address this issue.



VACCINES BASED ON ALLERGEN DERIVATIVES WITH REDUCED IGE AND T CELL REACTIVITY :

The hapten-carrier principle, which states that non-IgE-reactive allergen-derived peptides are covalently bound to carrier proteins, like viral proteins, is the foundation of a recently developed strategy for a safe allergy vaccine. In order to use carrier-based T cell assistance to produce IgG antibodies specific to allergens. T cells assist in the induction of carrier-specific and allergen-specific IgG by fusing peptides, which are roughly 25–40 amino acids long, that are derived from the IgE binding sites of allergens with a non-allergenic carrier protein[61].



CONCLUSION :

Over the past few decades, scientific, biotechnological, and clinical methods have identified a variety of immune components that contribute significantly to the pathophysiologic complexity of hypersensitivity reactions and ALLINF, providing new targets for immunopharmacology. This makes it possible for the creation and application of novel patient-centered immunomodulatory tools targeted at challenging allergic conditions, while not ignoring established players in both approved and experimental therapeutic approaches. For instance, glucocorticoids and H1 antihistamines have long been used to treat MC-derived mediators, which are exemplified by histamine and arachidonic acid-derived products or their target cells. It's interesting to note that ALLINF players also support immune surveillance and continue to offer useful targets that are utilized by contemporary precision and tailored pharmacotherapy techniques. Biologics that target IgE, cytokines, and cytokine receptors, as well as small-molecule inhibitors of signal transduction in key immune cells that shape ALLINF, are part of the arsenal of innovative immunopharmacological medications used to treat allergic diseases.Additionally, clinical research on allergic diseases is now testing a number of novel targets.

While new small-molecule Btk inhibitors target the modification of the crucial role played by Btk in B cell differentiation and MC activation, promising investigational immunomodulating drugs that are likely to play a significant role in therapeutic regimens for allergies in the near future include mAbs attenuating Th17 skewing or restoring T cell homeostasis via mitigation of the interaction between the checkpoints OX40 and OX40L. Additionally, current ALLINF research attempts to describe diagnostic and prognostic biomarkers and determine the disease phenotypes, endotypes, severity, and activity that are amenable to particular treatments for allergy diseases' crucial unmet clinical needs.Chronic, noncommunicable diseases like allergies are very common in societies where people lead more Westernized lifestyles. The definition of allergy is an adaptive

immune response to an antigen, known as an allergen, that can be swallowed, inhaled,applied to a mucocutaneous surface or injected.

Immunoglobulin E (IgE)-mediated mast cell activation causes the majority of allergic reactions to manifest as acute hypersensitivity reactions. This is followed by a complex type 2 immune response that includes eosinophils, T and B lymphocytes, and the interleukins IL-4 and IL-13 as hallmark cytokines.A late phase of inflammation and, in certain situations, a chronic inflammatory phase that results in tissue remodeling and functional impairment follow the early phase, which is marked by the release of mast cell mediators like histamine and tryptase. Al-Common examples of allergic conditions include IgE-mediated anaphylaxis, food allergies, drug allergies, insect venom allergies, allergic asthma, and allergic rhinitis and rhinoconjunctivitis.Medications that relieve symptoms, like glucocorticoids and H1 antihistamines, are part of the conventional therapeutic arsenal for treating allergic diseases.Patients with severe or uncontrollable presentations, primarily in asthma and atopic dermatitis, can now be managed more effectively thanks to the development of therapeutic monoclonal antibodies (mAbs) that target the players of the allergic inflammation.The anti-IgE mAbs omalizumab and ligelizumab, dupilumab (which binds the IL-4 receptor subunit (IL-4Ra) shared by IL-4 and IL-13 receptors), and the anti-IL-13 mAb tralokinumab are notable examples of antiallergic therapeutic biologics currently in use.Tezepelumab, which binds to the alarmin thymic stromal lymphopoietin (TSLP) released from epithelial cells; and mepolizumab, reslizumab, and benralizumab, which target the IL-5 receptor. Small-molecule medications like upadacitinib, abrocitinib, and baricitinib that target Janus kinase (JAK) signaling are examples of novel therapeutic interventions used primarily for atopic dermatitis.New small-molecule Bruton's tyrosine kinase and mAbs that inhibit the OX40-OX40L checkpoint interaction or attenuate Th17 skewing are promising investigational immunomodulatory medications that are anticipated to play a significant therapeutic role in the near future.

REFERENCES:

1. Takano H, Inoue K. Environmental pollution and allergies. J Toxicol Pathol. 2017;30(3):193–199.

2. Shin YH, Hwang J, Kwon R, et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Allergy. 2023;78(8):2445–2459.

3. Gonçalo M, Calderón MA, Demoly P, et al. Allergy in the World Health Organization's International Classification of Diseases (ICD)-11. Allergy. 2022;77(1):13-19.

4.Akdis CA, Akdis M. Mechanisms of immune-regulation in allergic disease. J Allergy Clin Immunol. 2020;145(1):24–34.

5. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704.

6. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nat. (review of early/late phases) – see The development of allergic inflammation. Nat Rev Immunol. 2008;8(8):553–565.

7. Artis D, Spits H. The role of ILC2s and Th2 cells in type 2 immune responses (helminths vs allergy). Nat Rev Immunol. 2015;15(1):21–33.

8. Halim TYF, Steer CA, Mathä L, Gold MJ, Martinez-Gonzalez I, McNagny KM, Takei F. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-type immune responses. Immunity. 2014;40(3):425–435. (or similar ILC2-Th2 review) — see OR of ILC2 role.

9. Barnes PJ. The pathophysiology of allergic rhinitis: impact of therapeutic intervention. J Allergy Clin Immunol. 1994;94(6 Pt 1):1297–1310.

10. Kim JH, Cho YS. Early and late phase reactions in allergic rhinitis. Asia Pac Allergy. 2019;9:e24. (or similar review) — see diagram in review: "Early and late phase reactions in AR." Perkin MR. The hygiene hypothesis for allergy – conception and evolution. Front Allergy. 2022;3:1051368.

11. Hoskinson C, Medeleanu MV, Reyna ME, et al. Antibiotics within first year are linked to infant gut microbiome disruption and elevated atopic dermatitis risk. J Allergy Clin Immunol. 2024

12. Azad MB, Konya T, Guttman DS, et al. Infant gut microbiota and the hygiene hypothesis of allergic disease: impact of household pets and siblings on microbiota composition and diversity. Ann Allergy Asthma Immunol. 2013;111(2):128–133.

13. Ptaschinski C, et al. Early-life risk factors which govern pro-allergic immunity. Seminars in Immunopathology. 2024

14. Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB. The hygiene hypothesis: current perspectives and future therapies. Immunotherapy. 2015;7(1):53–70.

15. Moffatt MF, Gut IG, Demenais F, et al.; GABRIEL Consortium. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2007;356(12): 1104–1116.

16. Gern JE. Immunological and genetic aspects of asthma and allergy. Immunol Rev. 2011;242(1):10–25.

17. Ke X, Penke LR, Vandivere-Landry B, Galanter N, Gignoux CR. Epigenetics in asthma and allergy: mechanisms and clinical implications. Allergy. 2020;75(9):2122–2142.

18. Bin L, Leung DYM. IL-4/IL-13–mediated signaling in atopic dermatitis: pathogenic and therapeutic implications. Eur J Immunol. 2017;47(5):765–774.

19. Koppelman GH, Asai Y, van der Sluis S, et al. Meta-analysis in genome-wide association studies identifies CDHR3 as a susceptibility locus for early childhood asthma with exacerbations. Nat Genet. 2013;45(8):962–968.

20. Ebner S, Kopp M, Mayer G, et al. Genetic and epigenetic aspects of atopic dermatitis. Expert Rev Clin Immunol. 2020;16(5):483–492.

21. Ober C, Yao T-C. The genetics of asthma and allergic disease: a 21st century perspective. Immunity. 2011; 35(4): 618–628.

22. Galli SJ, Tsai M. Mast Cells as Key Players in Allergy and Inflammation. J Allergy Clin Immunol. 2017; 140(2): 417–425.

23. Kraft S, Kinet JP. New developments in FceRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365-378.

24. Acharya M, Borland G, Edkins AL, et al. CD23/FcεRII: molecular multi-tasking. Clin Exp Immunol. 2010;162(1):12-23.

25. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nat Rev Immunol. 2008;8(4): 294-307.

26. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.

27. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.

28.Guilliams M, Ginhoux F, Jakubzick C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571-578.

29. Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA. Specific migratory dendritic cell type rapidly transport antigen from the airway lumen to T cells. J Exp Med. 2001;193(1):51-60.

30. Plantinga M, Guilliams M, Vanheerswynghels M, et al. Conventional dendritic cells and lung dendritic cell subsets in allergic inflammation. J Allergy Clin Immunol. 2013;132(2):287-300.

31.Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10(4):225-235.

32.Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336.

33.Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the "Swiss-Army knife" of the immune system. Nat Rev Immunol. 2008;8(7):511-522.

34. Akbari O, Faul JL, Hoyte EG, et al. $CD4^+$ invariant NKT cells are required for the development of allergen-induced airway hyperreactivity. Nat Med. 2003;9(5):582-588.

35. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181(6):4089-97.

36. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454-67.

37. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 and TGF-β induce the Th9 cell phenotype and allergic inflammation in vivo. Nat Immunol. 2008;9(12):1341-6.

38.Kim YM, Chung HT, Kim SS, Han JA, Yoo YM, Kim KM, et al. Resveratrol inhibits inducible nitric oxide synthase expression in macrophages activated by lipopolysaccharide. Br J Pharmacol. 1999;126(3):691–6.

39. Temann UA, Laouar Y, Eynon EE, Homer RJ, Flavell RA. IL-9 leads to airway inflammation and hyperresponsiveness in transgenic mice. J Clin Invest. 2007;109(1):29-39.

40. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of T(H)2 cytokines by adipose tissue–associated c-Kit+Sca-1+ lymphoid cells. Nature. 2010;463(7280):540-4.

41. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367-70.

42. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87.

43. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199(11):1567-75.

44. van de Veen W, Stanic B, Wirz OF, Jansen K, Globinska A, Akdis M. Role of regulatory B cells in immune tolerance to allergens. Allergy. 2020;75(3):522-34.

45. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147-74.

46. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12(2):117-29.

47. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Regulation of basophil functions and survival by cytokines. Trends Immunol. 2009;30(7):330-7.

48. Schroeder JT. Basophils: emerging roles in the pathogenesis of allergic disease. Immunol Rev. 2011;242(1):144-60.

49. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-54.

50. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK–STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.

51.Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84.

52. Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2000;143 Suppl 49:5–8.

53. Krieg AM.CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012;22(2):77–89.

54. Rasooly R, Dozmorov MG, Li X, et al. TLR4 inhibition by NI-0101 modulates innate immune pathways in humans. Clin Transl Sci. 2021;14(5):1908–21.
Gantier MP, Irving AT, Kaparakis-Liaskos M, et al. Genetic and pharmacological inhibition of TLR2 reduces inflammatory disease. J Immunol. 2010;184(3):1518–28.

55. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov. 2008;7(1):41–54.

56. Zampeli E, Tiligada E. The role of the histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol. 2009;157(1):24–33.

57.Gómez-Cadena A, Saldarriaga MP, Duque JE, et al. Plant-derived immunomodulators: overview of phytochemicals regulating immune responses. Phytother Res. 2021;35(4):1956–75.

58. Jakob T, Purohit A, Reisinger J, et al. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. J Allergy Clin Immunol. 2012;129(6):1577–84.

59. Pauli G, van de Veen W, Willersinn A, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(4):951–60.

60. Kieffer M, Mueller U, Hatzelmann A, et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen–allergic patients: a multicenter, double-blind, placebo-controlled study. Allergy. 2015;70(8):933–41.

61.Valenta R, Campana R, Focke-Tejkl M, Niederberger V. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides. J Allergy Clin Immunol. 2016;137(2):351–357.